The Health Products Regulatory Authority has published the 105^th edition of its Drug Safety Newsletter. 

This issue provides information on pregabalin and Direct Oral Anticoagulants (DOACs) including:

• Pregabalin

Respiratory depression without concomitant use of opioids or other CNS depressants

• Direct oral anticoagulants (DOACs)

Reminder of the importance of adhering to product information and existing measures to minimise the known risk of haemorrhage

• Reporting of suspected adverse reactions
• Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

For further details please click here.